OmicsAI Delivers Oral Presentation at World-Leading AI Conference...Targeting Global Precision Medicine Market with G2L Technology

OmicsAI, an artificial intelligence (AI)-based precision medicine startup, is emerging as a game changer that could reshape the global precision medicine market, armed with its proprietary "G2L (Giga-scale to Large-scale)" technology.

OmicsAI announced on the 23rd that it had delivered an oral presentation on its cancer-diagnosis-specialized AI model research results at a workshop hosted by the Association for the Advancement of Artificial Intelligence (AAAI), the world's most prestigious AI conference. Only a small number of papers are selected for oral presentations out of thousands of submissions, and being chosen is seen as international recognition of the company's technological capabilities.

The core competitiveness of OmicsAI lies in its independently developed G2L technology. Conventional medical AI models have continuously expanded the number of parameters to improve accuracy, but this has led to practical limitations such as enormous computational costs, slow processing speeds, and hardware constraints in hospital settings.

OmicsAI has directly tackled these issues. It succeeded in radically reducing the model size to about 15% of the original, while fully maintaining the performance of a large model with 190 million parameters.

A company representative commented, "It is an innovation comparable to implementing the intelligence of a supercomputer on a single laptop," adding, "By slimming down the model and resolving hardware constraints in hospitals, we will significantly accelerate commercialization in real-world clinical settings."

Securing "robustness" for real-world deployment is also a key focus of this announcement. Traditional cancer-diagnosis AI systems have long suffered from severe performance fluctuations depending on differences among hospitals in scanner devices, staining methods, and data quality.

OmicsAI's model is designed to maintain stable accuracy even under such environmental variability, and has been evaluated as having the level of completeness needed for immediate use in real clinical environments, going beyond laboratory conditions.

OmicsAI is pursuing a strategy to reduce proteomics analysis costs, which currently amount to tens of millions of won, by combining AI modeling technology with an automation platform. The company plans to lower analysis costs while improving diagnostic accuracy, thereby expanding demand for high-precision analysis among pharmaceutical companies, research institutions, and large hospitals. Through the popularization of analysis, it aims to build a virtuous cycle structure in which data inflow and revenue generation reinforce each other.

Shin Dongmyung, CEO of OmicsAI, said, "Our goal is not simply to develop an outstanding algorithm, but to build a diagnostic platform that medical professionals around the world can trust and use easily," adding, "This AAAI oral presentation is an important milestone for our entry into the global market."